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ABSTRACT 
 
Objectives  
Non-illicit alternatives to controlled drugs, known as Novel Psychoactive Substances (NPS), have recently 
risen to prominence. They are readily available, with uncertain pharmacology and no widely available 
assay. Given that psychiatric patients are at risk of comorbid substance abuse, we hypothesized that NPS 
use would be present in the psychiatric population, and sought to determine its prevalence and investigate 
the characteristics of those who use these drugs with a retrospective review of discharge letters. 
 
Setting 
General adult inpatient wards of a psychiatric hospital in a Scottish city. 
 
Participants 
All adult inpatients (18-65) discharged from general psychiatric wards between 1/7/14 and 31/12/14. Of 
the 483 admissions identified, 46 were admissions for maintenance ECT and were excluded. Of the 
remaining 437 admissions, 49 discharge letters were unobtainable, leaving 388 admissions to analyze. 
 
Primary outcome measure  
The mention, or lack thereof, of NPS use in discharge letters was our planned primary outcome measure 
and was also the primary outcome measure we used in our analysis.  
 
Results   
NPS use was identified in 22.2% of admissions, contributing to psychiatric symptoms in 59.3%. In 
comparison to non-users, NPS users were younger (p<0.01), male, and more likely to have a forensic 
history ((p<0.001) for both). The diagnosis of drug-induced psychosis was significantly more likely in NPS 
users (p<0.001, odds ratio (OR) 18.7, 95% confidence intervals (CI) 8.1-43.0) and the diagnosis of 
depression was significantly less likely (p<0.005, OR 0.133, CI 0.031-0.558). Use of cannabis was 
significantly more likely in NPS users (p<0.001, OR 4.2, CI 2.5-7.1), as was substitute opiate prescribing 
(p<0.001, OR 3.7, CI 1.8-7.4). 
 
Conclusions   
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NPS use was prevalent amongst young, male psychiatric inpatients, in particular those with drug-induced 
psychosis and often occured alongside illicit drug use.  
 
Trial Registration & Interventions – Not Applicable. No secondary outcome measures. 
 
STRENGTHS and LIMITATIONS. 
 
Strengths 
 
• We provide estimates of the prevalence and potential clinical relevance of NPS use in recently 
discharged psychiatric in-patients. 
• We have demonstrated several statistically significant relationships regarding the demographics of 
psychiatric in patients who use NPS. 
• We have laid the foundations for further work to investigate the relationship between NPS use and 
psychosis. 
 
Limitations 
 
• We cannot infer causal relationships from our results. 
• We relied upon discharge letters, potentially introducing reporting bias. 
• Our results refer to NPS as a uniform group, when in fact they are a heterogeneous group of 
psychoactive substances, which are likely to be used by differing groups of psychiatric in patients.
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INTRODUCTION 
 
Background 
Illicit drug use has long been recognized as a public health concern in Scotland and the rest of the United 
Kingdom, with 2013 survey data suggesting that 6.2% of adults had used drugs in the last year[1]. This rate 
has been falling year on year since the 2008/2009 survey. However, in recent years new classes of drugs 
with structures not controlled under the law have emerged, in addition to the ‘classic’ drugs of abuse. They 
are known as Novel Psychoactive Substances (NPS) and their alleged non-illicit status has led the media to 
label them as ‘legal highs’. 
 
NPS are defined by the UK Advisory Council on the Misuse of Drugs as ‘psychoactive drugs which are not 
prohibited by the United Nations Single Convention on Narcotic Drugs or by the Misuse of Drugs Act 
1971, and which people are seeking for intoxicant use’[2]. The blanket terminology of ‘NPS’ covers 6 
distinct groups; synthetic cannabinoids, phenethylamines, cathinones, plant based substances, piperazines 
and ketamine. Since the rapid and well publicised surge in mephedrone use in 2009[3], the emergence of 
NPS as drugs of abuse has represented a new challenge both to lawmakers and healthcare workers. 
 
The total number of NPS reported to the UNODC stood at 348 in December 2013, a large increase on the 
251 documented in July 2012[4], illustrating the growing nature of the problem. Their popularity stems 
largely from their ready availability online and in shops[5] and their alleged non-illicit status[6]. The point 
that their legality does not equate with safety has been made many times[7] They are often synthesized by 
modifying the structure of controlled drugs and, as such, discovery of new substances is hypothesized to be 
a continuous phenomenon[6], with current estimates suggesting that on average one new NPS is made 
available online in the EU every week[5]. The time lag between their recognition by policy makers and 
becoming controlled means that their consumption is unlikely to be diminished under current legislation; 
however the announcement of the Psychoactive Substances Bill in May 2015 may lead to changes in 
availability, given its implications for their future legal status[8]. 
 
NPS supply is unregulated, and, as such, there is significant variation in content between substances which 
are labeled as being the same[9]. This variety, coupled with the heterogeneous pharmacology of these 
substances, makes characterizing their effects problematic.  As such it is unsurprising that they have 
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unpredictable toxicological and psychiatric effects[10], with documented cases of psychosis[11], 
poisoning[12] and death[13]. 
 
Psychiatric patients have an increased rate of comorbid substance abuse compared to the general 
population[14], and recent studies show that the same trend is true of NPS use[15]. Evidence suggests that 
psychiatric patients with comorbid substance abuse have poorer clinical outcomes, cost health services 
more [16], and have an increased number of psychiatric admissions[17] than those without. Furthermore, it 
has been suggested that drug use can precipitate the emergence of psychiatric symptoms in at-risk 
individuals[18], and, from case reports, it appears that NPS use has been implicated in the emergence of 
psychotic symptoms[11]. A study published in 2013 showed that 13% of patients attending mental health 
services were using head shop drugs (a term commonly used to refer to NPS), with 54% reporting adverse 
effects upon their mental health [19] It is likely that psychiatric services will encounter many of the 
consequences of increasing NPS use. 
 
The relative novelty of NPS as substances of abuse, and the rapid fluctuations in the popularity of 
individual substances, mean that they currently have a limited evidence base, with the recent Novel 
Psychoactive Treatment UK Network (Neptune) [20] report representing the first cohesive attempt in the 
UK to collate knowledge and propose management approaches on the issue. NPS use by psychiatric 
patients and the role it plays in psychiatric inpatient admission has even less evidence, prompting our 
current attempt at its characterization. 
 
Objectives 
We hypothesized that NPS use would be present in a proportion of admissions to general adult psychiatric 
wards in Edinburgh. Our aims were to quantify the proportion of inpatient admissions which involved NPS 
use, and then to characterize the group of NPS users, in comparison with the non-NPS using patients. We 
used a retrospective case note review approach to maximize the included population. We looked for 
differences in demographics, mental health diagnosis, use of Mental Health Act, length of admission, forensic 
history and comorbidity with other substance misuse. We also sought to identify patterns of use by recording 
the substance being used and route of administration where this information was available. 
 
 
 
Page 5 of 28
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For peer review only
6  
 
METHODS 
 
Study Design and Setting 
This was a cross sectional survey conducted as a retrospective review of electronic discharge letters for all 
patients discharged from general adult psychiatric wards in the Royal Edinburgh Hospital, a large urban 
psychiatric hospital, between 1st July 2014 and 31st December 2014.  
 
Participants 
483 admissions were identified using the electronic patient record system. The duration of 6 months was 
chosen to provide an accurate representation of the population within the time constraints available. 
 
Data Collection 
The data collection was carried out by a 4th year undergraduate medical student at Edinburgh University. 
Of the 483 admissions identified, 46 were admissions for maintenance ECT and were excluded. Of the 
remaining 437 admissions, 49 discharge letters were unobtainable, leaving 388 admissions to analyze 
(representing 88.8% of the identified admissions). 
 
In 13 of these 388 admissions the discharge letter covered two separate admissions for the same patient in a 
short space of time. The information was coded twice, for each date of admission, to give a fair 
representation of service access. 
 
Data from these 388 admissions were recorded using the collection tool detailed in supplementary file 1. 
Information not included on the letter was coded as ‘not available’, and this applied particularly to 
‘substance use’, ‘forensic history’ and ‘custodial sentence’. The patient’s age reflects their age at 
admission, and the primary diagnosis reflects that stated on the discharge letter, meaning it is likely to 
correspond to the diagnosis relevant to admission. Mention of illicit substance use at any level was 
recorded as a positive finding, with the exception of alcohol, which was recorded only when the discharge 
letter suggested harmful use, either explicitly or with reference to consumption in line with an ICD-10 
diagnosis of harmful use or alcohol dependence. 
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When recording NPS use, we adopted a definition based on those used by the European Monitoring Centre 
for Drugs and Drug Addiction (EMCDDA)[5] and Neptune[20], defining them as a group of psychoactive 
compounds that emerged as alternatives to those controlled by the United Nations conventions, which may 
pose a public health threat comparable to that posed by substances listed in these conventions[5]. Some of 
these substances are now subject to legal control in the UK, however the term ‘legal high’ in discharge 
letters was deemed as evidence of NPS use given the widespread use of the term in reference to substances 
classified as NPS by patients and healthcare workers[21]. Due to a lack of information regarding the 
constituents of many substances, they were sub-divided into cannabinoids and stimulants, as opposed to the 
more stringent groups detailed in the introduction. 
 
Statistical Methods 
IBM SPSS Statistics version 22.0.0.1 was used for statistical analysis. The χ2 test was used to compare 
differences with regards to gender, primary diagnosis, substance use, forensic history, custodial sentence 
and use of the Mental Health Act. Fisher’s Exact Test was used to calculate odds ratios. Student’s t test was 
used to assess differences in length of stay and age. 
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RESULTS 
 
Figure 1 details the prevalence of NPS use, including characterization of individual NPS into stimulant or 
cannabinoid subtypes. Intravenous (IV) use was only noted for stimulants, and the rates are included due to 
the importance of intravenous use as a public health concern. NPS use was noted in 22.2% (n=86) of 
discharge letters, with 59.3% (n=51) of these stating that NPS use had contributed to the development of 
psychiatric symptoms relevant to the admission.
Table 1 details the demographic characteristics of NPS users and non-NPS users. There was a higher 
prevalence of males in the NPS users (69.8%) than the non-NPS users group (43.7%). This difference was 
shown to be statistically significant (p<0.001), with males more likely to be NPS users than females (odds 
ratio (OR)=2.9; 95% confidence interval (CI)=1.7-4.8). 
 
The data for employment and home circumstances did not show any statistically significant difference. 
NPS users were significantly more likely to have a forensic history (p<0.001, OR=3.2; 95% CI=2.0-5.3) 
and previous custodial sentences (p<0.001, OR=5.0; CI=2.6-9.3) than non-NPS users. There was no 
statistically significant difference between rates of detention under the Mental Health Act. 
 
Figure 2 shows that there was no statistically significant difference between the length of stay for those 
who used NPS and those who did not. 
 
Figure 3 illustrates the primary diagnoses of NPS users and non-NPS users. The diagnosis of drug-induced 
psychosis was significantly higher in NPS users, with 29 cases where NPS use was documented and 8 
where it was not (p<0.001, OR=18.7; 95% CI=8.1-43.0). Conversely, the prevalence of depression was 
significantly lower in NPS users, with 2 cases where NPS use was documented and 46 where it was not 
(p<0.005, OR=0.133; 95% CI=0.031-0.558).  
 
Figure 4 shows substance use (other than NPS) by NPS users and non-NPS users. NPS users had a higher 
incidence of use of all substances except benzodiazepines and GBL. This difference was statistically 
significant for cannabis (p<0.001, OR=4.2; 95% CI=2.5-7.1) and substitute opioid use (p<0.001, OR=3.7; 
95% CI=1.8-7.4). Of the 86 admissions with documented NPS use, 20 had no other documented comorbid 
substance abuse.
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  NPS Users 
(n=86) 
 
 
Non-NPS 
Users 
(n=302) 
 
Mean Age (sd)  36.1 (9.4)
+
  42.5 (12.5)
+
  
      
Gender Male 60 
*
 69.8% 132 
*
 43.7% 
 Female 26 
*
 30.2% 165 
*
 54.6% 
 Transgender 
^
 0  0% 5  1.7% 
      
Employment Unemployed 51  59.3% 190 62.9% 
 Student 3 3.5% 9 3% 
 Employed 5 5.8% 49 16.2% 
 Self-employed 1 1.2% 9 3% 
      
Home Circumstances Independent 57 66.3% 241 79.8% 
 Supported 10 11.6% 25 8.3% 
 Homeless 12 14% 27 8.9% 
      
Forensic History  44
*
 51.2% 74
*
 24.5% 
      
Previous Custodial 
Sentence 
 
 
25
*
 29.1% 23
*
 7.6% 
      
Use of Compulsory 
Measures under Mental 
Health Legislation 
 30 34.9% 105 34.8% 
Table 1 – Demographic Information for NPS users and non NPS users. 
+ Denotes statistically significant difference between NPS users and non NPS users (t-test)  p<0.01. 
* Denotes statistically significant difference, between NPS users and non NPS users (χ²)  p<0.001. 
^ Transgender data excluded from statistical analysis due to low numbers. 
NB – data missing for employment status in 26 NPS users and 45 non-NPS users. Data missing for home circumstances in 7 NPS 
users and 9 non-NPS users. 
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DISCUSSION 
 
We hypothesized that NPS use would be present in psychiatric admissions and found that 22.2% of  
discharge letters over a six month period identified NPS use. Furthermore, in 59.3% of cases of NPS use, it 
was suggested by the treating team that the NPS had contributed to the patient’s psychiatric symptoms, 
although this cannot be proven by this study. 
 
Our results also contribute to the emerging evidence regarding local NPS use. The discharges mentioned 
only stimulant NPS and synthetic cannabinoids. This is in line with findings by CREW 2000, whose survey 
suggested that 96% of NPS use in Edinburgh fell into either of these two categories[22]. Stimulant NPS  
use was identified in discharges more than three times as frequently as synthetic cannabinoid use. 
Cannabinoids have elsewhere been identified as the more common NPS sub type, with estimates 
suggesting that they account for 40% of NPS currently in circulation[6]. This might suggest that either 
stimulants are more commonly used in Edinburgh, or that their use is more likely to precipitate psychiatric 
symptoms leading to admission. 
 
Stimulant NPS use also carries the additional concern of intravenous (IV) administration. In our survey the 
stimulant NPS ‘Burst’ was injected in 75% of cases where it was mentioned (see supplementary file 2 for 
NPS subtype frequency). Intravenous drug use has well recognized public health implications[22]. 
Additionally, when injecting stimulant NPS the effects are short lived, leading to more frequent injecting. 
Furthermore, many NPS contain microcrystalline cellulose[21], which does not dissolve, potentially 
leading to blocked veins and abscesses. Current estimates suggest that ‘Burst’ is injected in roughly 20% of 
users[22]; however our prevalence of 75% was much higher than this. This discrepancy may suggest that 
IV ‘Burst’ use could be more likely to precipitate psychiatric symptoms than other routes of administration. 
 
We found that NPS use was more common in younger males, which is in agreement with previously 
published findings which indicated a higher rate of head shop drug (NPS) use amongst those younger than 
35 and amongst males [19]. We also found that NPS users were more likely to have served a custodial 
sentence or have other forensic history in comparison to non-users. This follows previously documented 
trends in the use of controlled substances and alcohol by psychiatric patients[23]. Homelessness is often 
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noted as associated with substance abuse, although we did not detect a statistically significant difference in 
this respect. 
 
Diagnostically, we found a statistically significant relationship between drug-induced psychosis and NPS 
use, as shown in Figure 3, with a large odds ratio, suggesting a strong association between the two 
variables (OR 18.7). It has been demonstrated that synthetic cannabinoids have a greater propensity to 
induce psychosis than cannabis[24], with reports of ‘spiceophrenia’ (‘spice’ being a form of synthetic 
cannabinoid) in the literature[25]. Research has also demonstrated that synthetic cocaine has a longer half-
life than its illicit derivative[26], and amphetamine type stimulants have been strongly associated with 
psychosis[27]. Recent research has shown that over half of ‘head shop drug’ users attending adult mental 
health services reported adverse effects on their mental health, in many cases manifesting as symptoms of 
psychosis [19]. In the context of previously published literature, our finding of an association between 
NPS use and drug-induced psychosis prompts the need for further investigation as a causal link cannot be 
inferred given the design of our study.  
 
Figure 3 shows a negative association between depression and NPS use (OR 0.13), with very few instances 
of the two occurring together. There is extensive research linking depression with cannabis[28] and 
alcohol[29] consumption and this is therefore a curious result, particularly given that many NPS available 
are synthetic cannabinoids, with similar effects to cannabis. It may be the case that lack of motivation or 
limited social opportunities as a consequence of depression may be at the root of this phenomenon, or that 
people with depression preferentially use other drugs. This requires further research. It is also worth noting 
that those with documented NPS use include patients with multiple other diagnoses, such as schizophrenia 
and emotionally unstable personality disorder. 
 
Despite the fact that NPS may be attractive due to their alleged non-illicit status, it has been shown that 
they are often added to a pre-existing repertoire of controlled substance use[30]. We found a significantly 
higher rate of cannabis and substitute opiate use by NPS users in comparison to non-NPS users. NPS 
pharmacology is notoriously unpredictable, and this is likely to be exacerbated by poly-substance use. 
Psychiatric patients with multiple substance misuse disorders are shown to have higher rates of psychiatric 
comorbidity[18], and NPS use may be further exacerbating the problem. Although the nature of the 
association between cannabis use and psychosis is controversial[31], the high coexistence of NPS and 
cannabis use is of concern, particularly in light of the previously noted relationship between NPS use and 
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drug-induced psychosis. Of note, 20 patients with documented NPS use had no documented comorbid 
substance use, which suggests that some NPS users may represent a different population to ‘classic’ drug 
users and that this may include otherwise drug-naïve individuals. 
 
NPS use was not shown to be related to an increased length of stay, or increased use of compulsory 
measures under mental health legislation, as shown in Figure 2. This may be due to our small sample size; 
however these two variables are likely to be multifactorial, and it is not surprising that their association 
with NPS use alone is not marked. 
 
Limitations and Further Work 
Our study had several limitations. The most significant of these was the fact that we relied on discharge 
letters to collect our data. Given the lack of widely available assays for the detection of NPS use, we were 
limited in our choice of study design. Relying on data recorded in discharge letters could have led to 
reporting bias (for example NPS use may not have been included where it was not felt to be relevant, 
leading to possible under reporting of NPS use). Knowledge of NPS is lacking in healthcare workers, with 
surveys among doctors showing a lack of confidence surrounding the subject [32]. This is in keeping with 
the fact that in only 39 of the 86 letters where NPS use was identified was the NPS itself named. The 
discharge letters were not standardized, and therefore omissions and varying interpretations by the 
doctors writing them will have introduced a degree of bias. Similarly, when recording other substance 
use we did not record toxicology screens, relying instead on what was written in the discharge letter, 
such that this data was also subject to reporting bias. The cross-sectional nature of our data collection 
meant that we were unable to infer causal relationships. 
 
Our sample size was small and further subdivision by diagnosis and comorbid substance use resulted in 
smaller sub-groups, meaning that the statistical values demonstrated should be interpreted with caution. 
Furthermore we could not include data for the 49 unavailable discharge letters, leading to an incomplete 
data set. 
 
As NPS constitute such a broad group of substances, with varying psychoactive effects, any conclusions on 
their use from our study should be drawn with caution. The associations we have demonstrated refer to 
NPS as a homogenous group. Whilst we have attempted a crude division into synthetic cannabinoid and 
stimulant NPS, further work should focus upon investigating the NPS classes as separate entities. There is, 
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however, an inherent problem in NPS categorization due to the lack of accurate information regarding their 
constituents. 
  
Generalizability 
This study was a cross sectional analysis of service users as opposed to a population study. The 
relationships we have highlighted may only apply to those who present to services, and perhaps even our 
local services, rather than the whole population of NPS using psychiatric patients. Equally, due to the study 
design we cannot establish any causal relationships.  
 
Our study represents a good starting point for NPS research, but more work is required. A population study 
is needed to appropriately characterize who is taking NPS, which NPS they are taking and what effects they 
are having. Routinely available testing apparatus does not test for NPS use. When, and if, this becomes 
available, further research will be more accurate. A better understanding of the pharmacology and effects of 
NPS is vital, although this is likely to be problematic, given their ever-changing nature. If we have learnt 
anything about NPS, it is that their synthesis will continue to outweigh attempts to control them, and 
psychiatric patients are likely to continue to use them. For that reason it is essential that they become better 
understood, as their presence and the consequences of their use are unlikely to be diminished anytime soon. 
 
Authors’ Contributions 
Jack Stanley and Dr Rebecca Lawrence designed the study. Jack Stanley collected the data, with 
supervision from Dr Lawrence and Dr Daniel Mogford. Dr Mogford provided supervision and advice 
regarding statistical methods, and Prof. Stephen Lawrie supervised all aspects. Jack Stanley submitted a 
first draft as a student selected component project to the University of Edinburgh. All authors reviewed and 
commented on the final submitted paper. 
 
Competing Interests 
No, there are no competing interests. 
 
Funding 
None 
 
Data Sharing 
Page 13 of 28
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For peer review only
14  
No additional data available. 
 
References 
1.  2012/13 Scottish Crime and Justice Survey: Drug Use. 2014; Scottish Centre for Crime and 
Justice Research. University of Glasgow. http://www.gov.scot/Resource/0045/00453923.pdf (accessed 
19.3.15) 
2.  ACMD (Advisory Council on the Misuse of Drugs), Consideration of the Novel Psychoactive 
Substances (‘legal highs’) October 2011 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/119139/acmdnps2011.p
df (accessed 18.3.15) 
3. Forsyth AJ. Virtually a drug scare: Mephedrone and the impact of the Internet on drug news 
transmission. Int J Drug Policy 2012;23(3):198-209. 
4. United Nations Office on Drugs and Crime (UNODC). World Drug Report 2014. 
https://www.unodc.org/documents/wdr2014/World_Drug_Report_2014_web.pdf (accessed 16.3.15) 
5.  European Monitoring Centre for Drugs and Drug Addiction. (2012). European Drug Report 2012: 
Annual report on the state of the drugs problem in Europe. 
http://www.emcdda.europa.eu/publications/annual-report/2012 (accessed 16.3.15) 
6.  United Nations Office on Drugs and Crime (UNODC). The Challenge of New Psychoactive 
Substances. Global SMART Programme 2013. 
http://www.unodc.org/documents/scientific/NPS_2013_SMART.pdf (accessed 15.3.15) 
7. Corazza O, Schifano F, Farre M et al. Designer drugs on the internet: a phenomenon out-of-control? The 
emergence of hallucinogenic drug Bromo-Dragonfly. Curr Clin Pharmacol 2011;6(2):125-129. 
8. Home Office. Psychoactive Substances Bill. https://www.gov.uk/government/collections/psychoactive-
substances-bill-2015 (accessed 17.6.15)  
9. Brandt SD, Sumnall HR, Measham F et al. Analyses of secondgeneration ‘legal highs’ in 
the UK: Initial findings. Drug Test Anal 2010;2(8):377-382. 
10.  Peters FT  & Martinez-Ramirez JA. Analytical toxicology of emerging drugs of abuse. Ther Drug 
Monit 2010; 32(5), 532-539. 
11. Every-Palmer S. Synthetic cannabinoid JWH-018 and psychosis: an explorative study. Drug 
Alcohol Depen 2011;117(2):152-157. 
12. Gibbons S. 'Legal Highs'-novel and emerging psychoactive drugs: a chemical overview for the 
toxicologist. Clin Toxicol 2012;50(1):15-24. 
Page 14 of 28
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For peer review only
15  
13. McAuley A, Hecht G, Barnsdale L et al. Mortality related to novel psychoactive substances in 
Scotland, 2012: An exploratory study. Int J Drug Policy. 2015;26(5):461-467. 
14. Crawford V. Comorbidity of substance misuse and psychiatric disorders. Curr Opin Psychiatr 
1996;9(3):231-234. 
15. Martinotti G, Lupi M, Acciavatti T et al. Novel psychoactive substances in young adults with and 
without psychiatric comorbidities. BioMed Res Int 2014. 
16. Dickey B & Azeni H. Persons with dual diagnoses of substance abuse and major mental illness: their 
excess costs of psychiatric care. Am J Public Health 1996;86(7):973-977. 
17. Drake RE. Long-term course of substance use disorders among patients with severe mental 
illness. Psychiatr Serv 1995;46(3). 
18. Brady KT & Sinha R. Co-occurring mental and substance use disorders: the neurobiological effects of 
chronic stress. Focus (Am Psychiatr Publ) (2007); 5(2):229-239. 
19. Lally J, Higaya EE, Nisar Z, Bainbridge E & Hallahan B. Prevalence study of head shop drug usage in 
mental health services. The Psychiatrist 2013;37(2):44-48. 
20. Abdulrahim D & Bowden-Jones O, on behalf of the NEPTUNE Expert Group. Guidance on the 
Management of Acute and Chronic Harms of Club Drugs and Novel Psychoactive Substances. Novel 
Psychoactive Treatment UK Network (NEPTUNE). London, 2015 
21. Corazza O, Demetrovics Z, van den Brink W et al. ‘Legal highs’ an inappropriate term for ‘Novel 
Psychoactive Drugs’ in drug prevention and scientific debate. Int J Drug Policy 2013;24(1):82-83. 
22. CREW 2000. NPS at Crew Annual Report 2014-2015.  2015. https://1fec16444e7228ff2981-
b6e25eb72df69608d37cf0f90c328ddf.ssl.cf3.rackcdn.com/20150410%20-
%20NPS%20ANNUAL%20REPORT%20-%202015%20-%20FINAL%20-%202.pdf (accessed 28.4.15) 
23. Westermeyer J & Walzer V. Sociopathy and drug use in a young psychiatric population. Dis Nerv Syst. 
1975;36:673–677. 
24. Fattore L & Fratta W. Beyond THC: the new generation of cannabinoid designer drugs. Front 
Behav Neurosci, 2011;5. 
25. Papanti D, Schifano F, Botteon G et al. “Spiceophrenia”: a systematic overview of “Spice”related 
psychopathological issues and a case report. Hum Psychopharmacol 2013;28(4):379-389. 
26. McNabb CB, Russell BR, Caprioli D et al. Single chemical entity legal highs: assessing the risk for 
long term harm. Curr Drug Abuse Rev. 2012;5(4):304–19. 
27. Salo R, Flower K, Kielstein A et al. Psychiatric comorbidity in methamphetamine dependence. 
Psychiatry Res 2011;186(2-3):356–61. 
Page 15 of 28
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For peer review only
16  
28. Degenhardt L, Hall W & Lynskey M. Exploring the association between cannabis use and depression. 
Addiction 2003;98(11):1493-1504. 
29. Boden JM & Fergusson DM. Alcohol and depression. Addiction 2011;106(5):906-914. 
30. Moore K, Dargan PI & Wood DM. Do novel psychoactive substances displace established club drugs, 
supplement them or act as drugs of initiation? The relationship between mephedrone, ecstasy and cocaine. 
Eur Addict Res 2013;19(5):276-282. 
31. Arseneault L, Cannon M, Witton J et al. Causal association between cannabis and psychosis: 
examination of the evidence. Br J Psychiatry 2004;184(2):110-117. 
32. Simonato P, Corazza O, Santonastaso P et al: Novel psychoactive substances as a novel challenge for 
health professionals: results from an Italian survey. Hum Psychopharmacol 2013;28(4):324-331. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 16 of 28
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For peer review only
17  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 17 of 28
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For peer review only
18  
 
 
 
 
 
 
 
Page 18 of 28
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For peer review only
19  
Page 19 of 28
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For peer review only
 
 
Page 20 of 28
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For peer review only
  
 
 
* - n (NPS subtype) less than n (cannabinoid) and n (stimulant) combined due to poly NPS use. See 
supplementary file 2 for breakdown of individual NPS frequency.  
127x149mm (300 x 300 DPI)  
 
 
Page 21 of 28
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For peer review only
  
 
 
 
42x33mm (300 x 300 DPI)  
 
 
Page 22 of 28
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For peer review only
  
 
 
* - Denotes statistically significant difference, between NPS users and non NPS users (χ²) p<0.001.  
+ - Denotes statistically significant difference, between NPS users and non NPS users (χ²) p<0.005.  
 
42x33mm (300 x 300 DPI)  
 
 
Page 23 of 28
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For peer review only
  
 
 
* - Denotes statistically significant difference, between NPS users and non NPS users (χ²) p<0.001  
42x33mm (300 x 300 DPI)  
 
 
Page 24 of 28
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For peer review only
Page 25 of 28
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For peer review only 
NPS Sub Type  NPS Name  Frequency  IV use (% use as IV) 
Synthetic Cannabinoid  Exodus  4  ‐ 
  Diesel  1  ‐ 
  Clockwork Orange  1  ‐ 
  Voodoo Blue  1  ‐ 
  Voodoo Gold  1  ‐ 
  Psyclone  1  ‐ 
  ‘Herbal Legal Highs’  1  ‐ 
  ‘Synthetic Cannabinoids’  1  ‐ 
  Green Leaf  1  ‐ 
      ‐ 
Stimulants  Burst  16  12 (75%) 
  Ching  6  ‐ 
  Pink Panther  2  ‐ 
  Benzofury  2  ‐ 
  Boost  2  1 (50%) 
  Magic Crystals  2  ‐ 
  Synthcaine  1  ‐ 
  Ethylphenidate  1  ‐ 
  Mephedrone  1  ‐ 
  Go‐caine  1  ‐ 
  Bath Salts  1  ‐ 
  Monkey Dust  1  ‐ 
  Snow White  1  ‐ 
  El Blanco  1  ‐ 
  Powder  1  ‐ 
  Bliss  1  ‐ 
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STROBE Statement—Checklist of items that should be included in reports of cross-sectional studies  
 Item 
No Recommendation 
Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or the abstract 
[within the abstract under the design heading on page 2] 
(b) Provide in the abstract an informative and balanced summary of what was done 
and what was found [within the abstract under the results heading on page 2] 
Introduction 
Background/rationale 2 Explain the scientific background and rationale for the investigation being reported 
[within the introduction under the background heading on page 3] 
Objectives 3 State specific objectives, including any prespecified hypotheses [within the 
introduction under the objectives heading on page 4] 
Methods 
Study design 4 Present key elements of study design early in the paper [within the methods under 
the study design heading on page 5] 
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, 
exposure, follow-up, and data collection [within the methods under the data 
coll ction heading on page 5] 
Participants 6 (a) Give the eligibility criteria, and the sources and methods of selection of 
participants [within the methods under the data collection heading on page 5] 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect 
modifiers. Give diagnostic criteria, if applicable [outcomes within the methods 
under the data collection heading on page 5. Rest N/A] 
Data sources/ 
measurement 
8*  For each variable of interest, give sources of data and details of methods of 
assessment (measurement). Describe comparability of assessment methods if there is 
more than one group [N/A] 
Bias 9 Describe any efforts to address potential sources of bias [within the methods under 
the data collection heading on page 5 and discussed within the discussion under 
the limitations and further work heading on page 11] 
Study size 10 Explain how the study size was arrived at [within the methods under both study 
design and participants headings on page 5] 
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, 
describe which groupings were chosen and why at [within the methods under the 
statistical methods heading on page 6] 
Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding 
[within the methods under the statistical methods heading on page 6] 
(b) Describe any methods used to examine subgroups and interactions [N/A] 
(c) Explain how missing data were addressed [within the methods under the data 
collection heading on page 5] 
(d) If applicable, describe analytical methods taking account of sampling strategy 
[N/A] 
(e) Describe any sensitivity analyses [N/A] 
Results 
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially 
eligible, examined for eligibility, confirmed eligible, included in the study, 
completing follow-up, and analysed [within the methods under the data collection 
heading on page 5] 
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(b) Give reasons for non-participation at each stage [within the methods under the 
data collection heading on page 5] 
(c) Consider use of a flow diagram [Figure 1] 
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and 
information on exposures and potential confounders [within the results in table 1 on 
page 8] 
(b) Indicate number of participants with missing data for each variable of interest 
[within results section in the legend of table 1 on page 8. No missing data for 
other variables as we documented the mention or lack thereof of many variables 
in discharge letters] 
Outcome data 15* Report numbers of outcome events or summary measures [Our only outcome event 
is mention of NPS use or no mention. This is referred to explicitly throughout 
the results section on page 7]. 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and 
their precision (eg, 95% confidence interval). Make clear which confounders were 
adjusted for and why they were included [95% confidence limits quoted in results 
on page 7] 
(b) Report category boundaries when continuous variables were categorized [N/A] 
(c) If relevant, consider translating estimates of relative risk into absolute risk for a 
meaningful time period [N/A] 
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and 
sensitivity analyses [N/A] 
Discussion 
Key results 18 Summarise key results with reference to study objectives [within discussion on page 
9] 
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or 
imprecision. Discuss both direction and magnitude of any potential bias [within 
discussion under limitations and generalizability headings on page 11] 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, 
multiplicity of analyses, results from similar studies, and other relevant evidence 
[within discussion on page 9 and 10] 
Generalisability 21 Discuss the generalisability (external validity) of the study results [within discussion 
under generalizability heading on page 11] 
Other information 
Funding 22 Give the source of funding and the role of the funders for the present study and, if 
applicable, for the original study on which the present article is based [N/A] 
 
*Give information separately for exposed and unexposed groups. 
 
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and 
published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely 
available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at 
http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is 
available at www.strobe-statement.org. 
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